Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024

/PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the AUA...

Related Keywords

Chile ,Israel ,Oslo ,Norway ,San Antonio ,Texas ,United States ,New Zealand ,Hailong ,Yunnan ,China ,Canada ,Australia ,American ,Dan Schneider ,Hexvix Cysview ,Prnewswire Photocure ,David Moskowitz ,Sanjay Das ,Erik Dahl ,Cysview Hexvix ,Steven Williams ,Bladder Cancer Company ,Corporate Communications Norway ,American Cancer Society ,Oslo Stock Exchange ,Affairs Va Healthcare ,Veterans Affairs Healthcare System ,American Urological Association Annual Congress ,Equal Access ,Propensity Scored Matched Analysis ,Bladder Cancer Recurrence Analysis ,Veterans Affairs Healthcare ,Veteran Affairs ,Principal Investigator ,Blue Light Cystoscopy ,White Light Cystoscopy ,Bladder Cancer ,Pivotal Trial ,Real World Data ,American Cancer ,Photocure ,